SCHEMBL1497359

SCHEMBL1497359

C/C=C/C(=O)CCCC(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A6 Q4U2R8 2/20 0.52
OXER1 Q8TDS5 2/20 0.50
PPARG P37231 5/20 0.48
PPARA Q07869 4/20 0.48
LMNA P02545 2/20 0.46
ALOX12 P18054 2/20 0.45
KDM4E B2RXH2 1/20 0.44
TSHR P16473 3/20 0.43
NFKB1 P19838 1/20 0.43
PMP22 Q01453 1/20 0.43
AKR1B1 P15121 1/20 0.42
ABCC4 O15439 1/20 0.41
MAPT P10636 1/20 0.41
GPR84 Q9NQS5 2/20 0.41
PPARD Q03181 2/20 0.41
ALDH1A1 P00352 1/20 0.41
SLC22A8 Q8TCC7 1/20 0.41
TLR2 O60603 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1497361 1.00 SLC22A6 (0.52) SLC22A6OXER1PPARGPPARALMNA
SCHEMBL27429376 0.95 PPARG (0.53) SLC22A6PPARGPPARALMNAKDM4E
SCHEMBL25326213 0.95 PPARG (0.53) SLC22A6PPARGPPARALMNAKDM4E
SCHEMBL21238173 0.93 PPARG (0.56) SLC22A6PPARGPPARALMNAKDM4E
SCHEMBL1497341 0.85 LMNA (0.47) SLC22A6OXER1PPARGPPARALMNA
SCHEMBL1497338 0.85 LMNA (0.47) SLC22A6OXER1PPARGPPARALMNA
Glutarate SCHEMBL3883818 0.82 SLC22A6 (0.69) SLC22A6PPARGPPARALMNATSHR
SCHEMBL13835285 0.81 ALDH1A1 (0.41) OXER1PPARGPPARALMNAALOX12
SCHEMBL21894041 0.81 SOAT1 (0.38) OXER1PPARGPPARAALOX12KDM4E
SCHEMBL26032385 0.80 PPARG (0.41) OXER1PPARGPPARAALOX12KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240217960-A1 TRIAZINE DERIVATIVE AS COVALENT INHIBITORS OF PI3K UNIVERSITÄT BASEL (CH) 2024-07-04 US disclosed
US-20240217960-A1 TRIAZINE DERIVATIVE AS COVALENT INHIBITORS OF PI3K UNIVERSITÄT BASEL (CH) 2024-07-04 US disclosed
EP-2475375-A2 PI3 KINASE INHIBITORS AND USES THEREOF Avila Therapeutics, Inc. (US) 2012-07-18 EP disclosed
US-20110230476-A1 PI3 KINASE INHIBITORS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2011-09-22 US disclosed
WO-2011031896-A2 PI3 KINASE INHIBITORS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2011-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230476-A1 PI3 KINASE INHIBITORS AND USES THEREOF PIK3CA, PIK3CB, PIK3C2B SLC22A6 4751/4885OXER1 4408/4885PPARG 3630/4885
US-20240217960-A1 TRIAZINE DERIVATIVE AS COVALENT INHIBITORS OF PI3K PIK3R5, PIK3R1, PIK3R2 SLC22A6 3460/4885OXER1 2478/4885PPARG 3613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.